Literature DB >> 33199251

Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium.

William T Abraham1, Mitchell A Psotka2, Mona Fiuzat3, Gerasimos Filippatos4, JoAnn Lindenfeld5, Roxana Mehran6, Amrut V Ambardekar7, Peter E Carson8, Richard Jacob9, James L Januzzi10, Marvin A Konstam11, Mitchell W Krucoff3, Eldrin F Lewis12, Jonathan P Piccini3, Scott D Solomon13, Norman Stockbridge14, John R Teerlink15, Ellis F Unger13, Emily P Zeitler16, Stefan D Anker17, Christopher M O'Connor18.   

Abstract

The Heart Failure Academic Research Consortium is a partnership between the Heart Failure Collaboratory (HFC) and Academic Research Consortium (ARC), comprised of leading heart failure (HF) academic research investigators, patients, United States (US) Food and Drug Administration representatives, and industry members from the US and Europe. A series of meetings were convened to establish definitions and key concepts for the evaluation of HF therapies including optimal medical and device background therapy, clinical trial design elements and statistical concepts, and study endpoints. This manuscript summarizes the expert panel discussions as consensus recommendations focused on populations and endpoint definitions; it is not exhaustive or restrictive, but designed to stimulate HF clinical trial innovation.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Clinical trial; Definitions; Endpoints; Heart failure

Year:  2020        PMID: 33199251     DOI: 10.1016/j.jchf.2020.10.002

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN: 2213-1779            Impact factor:   12.035


  1 in total

Review 1.  Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.

Authors:  Mona Fiuzat; Carine E Hamo; Javed Butler; William T Abraham; Ersilia M DeFilippis; Gregg C Fonarow; Joann Lindenfeld; Robert J Mentz; Mitchell A Psotka; Scott D Solomon; John R Teerlink; Muthiah Vaduganathan; Orly Vardeny; John J V McMurray; Christopher M O'Connor
Journal:  J Am Coll Cardiol       Date:  2022-02-08       Impact factor: 27.203

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.